Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 25;23(10):2452.
doi: 10.3390/molecules23102452.

Discovery of CNS-Like D3R-Selective Antagonists Using 3D Pharmacophore Guided Virtual Screening

Affiliations

Discovery of CNS-Like D3R-Selective Antagonists Using 3D Pharmacophore Guided Virtual Screening

June Hyeong Lee et al. Molecules. .

Abstract

The dopamine D3 receptor is an important CNS target for the treatment of a variety of neurological diseases. Selective dopamine D3 receptor antagonists modulate the improvement of psychostimulant addiction and relapse. In this study, five and six featured pharmacophore models of D3R antagonists were generated and evaluated with the post-hoc score combining two survival scores of active and inactive. Among the Top 10 models, APRRR215 and AHPRRR104 were chosen based on the coefficient of determination (APRRR215: R²training = 0.80; AHPRRR104: R²training = 0.82) and predictability (APRRR215: Q²test = 0.73, R²predictive = 0.82; AHPRRR104: Q²test = 0.86, R²predictive = 0.74) of their 3D-quantitative structure⁻activity relationship models. Pharmacophore-based virtual screening of a large compound library from eMolecules (>3 million compounds) using two optimal models expedited the search process by a 100-fold speed increase compared to the docking-based screening (HTVS scoring function in Glide) and identified a series of hit compounds having promising novel scaffolds. After the screening, docking scores, as an adjuvant predictor, were added to two fitness scores (from the pharmacophore models) and predicted Ki (from PLSs of the QSAR models) to improve accuracy. Final selection of the most promising hit compounds were also evaluated for CNS-like properties as well as expected D3R antagonism.

Keywords: 3D-QSAR; CNS-like; D3R selective antagonist; molecular docking; pharmacophore; virtual screening.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Superimposed 3PBL protein-ligand docking of dopamine (green; endogenous D3R agonist), eticlopride (yellow; non-selective D3R antagonist) and R-22 (sky blue; selective D3R antagonist).
Figure 2
Figure 2
Workflows of this study.
Figure 3
Figure 3
Docking pose showing the interaction between R-22 and 3PBL residues. In the left-hand picture, the blue line shows Pi-Pi stacking, the purple line shows hydrogen bond interaction and the yellow-green line shows hydrophobic interaction.
Figure 4
Figure 4
Representative 3D-QSAR models: APRRR215 (upper) and AHPRRR104 (lower).
Figure 5
Figure 5
APRRR215 regression lines for the training (blue) and test (red) sets.
Figure 6
Figure 6
AHPRRR104 regression lines for the training (blue) and test (red) sets.
Figure 7
Figure 7
APRRR215 ROC curve and AUC.
Figure 8
Figure 8
APRRR 215 skeletal box-and-whisker plot.
Figure 9
Figure 9
Hit selection workflow.

Similar articles

Cited by

References

    1. Contreras F., Fouillioux C., Bolívar A., Simonovis N., Hernández-Hernández R., Armas-Hernandez M.J., Velasco M. Dopamine, hypertension and obesity. J. Hum. Hypertens. 2002;16:13–17. doi: 10.1038/sj.jhh.1001334. - DOI - PubMed
    1. Heidbreder C.A., Newman A.H. Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann. N. Y. Acad. Sci. 2010;1187:4–34. doi: 10.1111/j.1749-6632.2009.05149.x. - DOI - PMC - PubMed
    1. Gurevich E.V., Joyce J.N. Distribution of Dopamine D3 Receptor Expressing Neurons in the Human Forebrain: Comparison with D2 Receptor Expressing Neurons. Neuropsychopharmacology. 1999;20:60–80. doi: 10.1016/S0893-133X(98)00066-9. - DOI - PubMed
    1. Maramai S., Gemma S., Brogi S., Campiani G., Butini S., Stark H., Brindisi M. Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases. Front. Neurosci. 2016;10:451. doi: 10.3389/fnins.2016.00451. - DOI - PMC - PubMed
    1. Joyce J.N. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 2001;90:231–259. doi: 10.1016/S0163-7258(01)00139-5. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources